DDInter1144 DDInter1676
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Melphalan {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Melphalan {u} (Compound) resembles {v} (Compound) Levodopa
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
Melphalan {u} (Compound) binds {v} (Gene) SLC7A5
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Melphalan {u} (Compound) causes {v} (Side Effect) Radiation myelopathy
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Melphalan (Compound) resembles L-Phenylalanine (Compound)
Melphalan (Compound) resembles Levodopa (Compound)
Melphalan (Compound) treats ovarian cancer (Disease)
Melphalan (Compound) binds SLC7A5 (Gene)
Melphalan (Compound) upregulates DDB2 (Gene)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Melphalan (Compound) causes Radiation myelopathy (Side Effect)
Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab